Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3

Rhea-AI Filing Summary

Monopar Therapeutics officer Susan Rodriguez filed an initial statement of beneficial ownership on Form 3. She is listed as the company’s CCSO, and the filing does not report any insider stock transactions, focusing instead on establishing her status as a reporting officer.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rodriguez Susan

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE IL 60091

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/02/2026

3. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CCSO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Quan Vu, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Monopar Therapeutics (MNPR) Form 3 for Susan Rodriguez show?

The Form 3 for Monopar Therapeutics officer Susan Rodriguez records her status as a reporting insider. It identifies her role as CCSO and serves as an initial beneficial ownership statement, without detailing any specific stock buy or sell transactions.

Who is the insider named in Monopar Therapeutics (MNPR) latest Form 3 filing?

The insider named is Susan Rodriguez, an officer of Monopar Therapeutics. The filing lists her title as CCSO, formally recognizing her as a reporting person under SEC rules and triggering ongoing disclosure requirements for future qualifying stock transactions.

Does the Monopar Therapeutics (MNPR) Form 3 filing report any stock trades?

The Form 3 filing for Monopar Therapeutics officer Susan Rodriguez does not report any stock trades. Instead, it functions as an initial beneficial ownership disclosure, setting the baseline for any future insider transactions that may need to be reported separately.

Why is Monopar Therapeutics (MNPR) officer Susan Rodriguez filing a Form 3?

Susan Rodriguez filed a Form 3 because, as a CCSO at Monopar Therapeutics, she qualifies as an insider under SEC rules. Form 3 establishes her as a reporting person, providing a starting point for tracking future reportable equity holdings and transactions.

What insider role is disclosed for Susan Rodriguez at Monopar Therapeutics (MNPR)?

The filing discloses that Susan Rodriguez serves as CCSO at Monopar Therapeutics. This officer role makes her subject to insider reporting requirements, and the Form 3 documents her status as a person whose future equity transactions must be reported to the SEC.